Elicio Therapeutics Inc
Elicio Therapeutics Inc (ELTX) Covered Calls
As of September 22, 2026, ELTX has 3 covered call opportunities in the coming three months. Return ranges from 49.7 to 170.1% until expiration. Annualized return ranges from 87.5 to 1,052.0%. The nearest expiration is November 20, 2026. Maximum potential profit is $318.
Read more
Running ELTX covered calls helps you generate consistent income from Elicio Therapeutics Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Elicio Therapeutics Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best ELTX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if ELTX stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling ELTX covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Elicio Therapeutics Inc covered call is worth writing.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers.
The company is headquartered in Boston, Massachusetts.
Income-focused investors, long-term ELTX holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling ELTX covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Elicio Therapeutics Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile28.17% Subdued
- Market cap (M$)49
- 52 weeks high-88.31%
- 52 weeks low10.00%
- Analyst recommendationStrong Buy
1.40 - Target price$18.90
910.70% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-2.11
- EPS growth next 5 years-8.55%
As of September 22, 2026
| 2026-11-20 | 59 | 5.00 | 167.38 | 0.05 | 1.00 | 318.00 | 170.05 | 1052.03 | -2.67 | +0.50 | 396 | 0.95 |
| 2027-02-19 | 150 | 2.50 | 33.69 | 0.30 | 0.45 | 93.00 | 49.73 | 121.02 | -16.04 | +0.50 | 98 | 0.15 |
| 2027-05-21 | 241 | 2.50 | 33.69 | 0.45 | 0.80 | 108.00 | 57.75 | 87.47 | -24.06 | +0.62 | 2 | 0.35 |
As of September 22, 2026
Sell covered calls with the data behind you
Find the best ELTX covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→